Frank Rimerman Advisors LLC Has $391,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Frank Rimerman Advisors LLC lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,427 shares of the medical equipment provider’s stock after acquiring an additional 472 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Hologic were worth $391,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. General Partner Inc. acquired a new position in Hologic during the fourth quarter worth approximately $26,000. Groupama Asset Managment increased its position in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC increased its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. increased its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Trading Up 0.0 %

Shares of HOLX stock opened at $60.71 on Monday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.62 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The stock has a 50 day simple moving average of $67.18 and a 200 day simple moving average of $74.64. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.